We are live on
!
Find out more
CCM
Camber Capital Management Portfolio holdings
AUM
$1.07B
1-Year Est. Return
8.19%
This Fund
S&P 500
This Quarter
Est. Return
+0.51%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$1.9B
AUM Growth
+$148M
(+8.5%)
Cap. Flow
+$194M
Cap. Flow
% of AUM
10.22%
Top 10 Holdings %
Top 10 Hldgs %
63.78%
Holding
40
New
10
Increased
11
Reduced
7
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HCA Healthcare
HCA
|
+$89.7M |
| 2 |
Bausch Health
BHC
|
+$77.5M |
| 3 |
Cigna
CI
|
+$44M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
+$40.5M |
| 5 |
OraSure Technologies
OSUR
|
+$37.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GSK
GSK
|
+$102M |
| 2 |
Ascendis Pharma A/S
ASND
|
+$51.8M |
| 3 |
Glaukos
GKOS
|
+$28M |
| 4 |
SAGE
Sage Therapeutics
SAGE
|
+$21.8M |
| 5 |
TBIO
Translate Bio, Inc. Common Stock
TBIO
|
+$17.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 82.31% |
| 2 | Technology | 11.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Atara Biotherapeutics
ATRA
$76.1M
| $18.1M | 0.96% |
56,000
| – | – |
|
|
27
GSK
GSK
$106B
| $16.9M | 0.89% |
360,000
-2,040,000
| -85% | -$102M |
|
28
Immunovant
IMVT
$8.25B
| $15.4M | 0.81% |
438,800
-361,200
| -45% | -$10.9M |
|
|
DRNA
29
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $9.45M | 0.5% |
+525,000
| New | +$10.9M |
|
|
CBIO
30
Crescent Biopharma
CBIO
$626M
| $7.67M | 0.4% |
25,000
-5,000
| -17% | -$1.91M |
|
31
Sutro Biopharma
STRO
$421M
| $6.03M | 0.32% |
60,000
| – | – |
|
|
GBT
32
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $2.76M | 0.15% |
+50,000
| New | +$3.18M |
|
33
Vir Biotechnology
VIR
$1.49B
| $565K | 0.03% |
+16,464
| New | +$709K |
|
34
AngioDynamics
ANGO
$649M
| $252K | 0.01% |
+20,876
| New | +$198K |
|
|
35
Ascendis Pharma A/S
ASND
$16.8B
| – | – |
-350,000
| Closed | -$51.8M |
|
|
36
Glaukos
GKOS
$10.6B
| – | – |
-730,000
| Closed | -$28M |
|
|
SAGE
37
DELISTED
Sage Therapeutics
SAGE
| – | – |
-525,000
| Closed | -$21.8M |
|
|
TBIO
38
DELISTED
Translate Bio, Inc. Common Stock
TBIO
| – | – |
-1,000,000
| Closed | -$17.9M |
|
|
MNTA
39
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| – | – |
-450,000
| Closed | -$15M |
|
Similar funds
PP
SAF
NRD
FC
GIM
SC
BWA
CCP
Camber Capital Management's Q3 2020 Portfolio in Review
As of Q3 2020, Camber Capital Management held 40 positions worth $1.9B, up 8.5% from $1.75B the previous quarter. Its ten largest holdings account for 64% of the portfolio.
Camber Capital Management deployed $194M of net new capital in Q3 2020, opening 10 new positions and adding to 11 existing holdings. Its largest new stake was HCA Healthcare: 725,000 shares worth $90.4M.
By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 87% a quarter earlier, followed by Technology.
On the sell side, the largest reduction was GSK, an estimated $102M trimmed.
- Camber Capital Management's largest Q3 2020 buy was HCA Healthcare: 725,000 shares worth $90.4M.
- Camber Capital Management added most to Perrigo in Q3 2020, an estimated $31.4M increase.
- Camber Capital Management's biggest Q3 2020 reduction was GSK, cutting an estimated $102M.
- Camber Capital Management fully exited Ascendis Pharma A/S in Q3 2020, selling an estimated $51.8M.
- Camber Capital Management's ten largest holdings make up 64% of its $1.9B portfolio in Q3 2020.
- Camber Capital Management opened 10 new positions and closed 5 in Q3 2020.
- Camber Capital Management's portfolio value rose 8.5% quarter-over-quarter to $1.9B.
Based on Camber Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.